EcoDrugPlus

Histone Deacetylase 5

Ensembl ID : ENSOMYG00000044181
Gene Symbol: HDAC5
1 Cross references
191 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSOMYG00000027430
Gene Symbol: HDAC8
1 Cross references
203 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSOMYG00000036512
Gene Symbol: HDAC8
2 Cross references
202 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSOMYG00000034246
Gene Symbol: HCN4
1 Cross references
215 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSOMYG00000045853
Gene Symbol: HCN4
1 Cross references
213 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSOMYG00000045760
Gene Symbol: HCRTR2
2 Cross references
203 Possible Orthologues:

Inducible Nitric Oxide Synthase

Ensembl ID : ENSOMYG00000041648
Gene Symbol: NOS2
1 Cross references
160 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSOMYG00000023786
Gene Symbol: IMPDH1
1 Cross references
251 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSOMYG00000010190
Gene Symbol: IMPDH1
1 Cross references
251 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSOMYG00000039979
Gene Symbol: INSRA
1 Cross references
204 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSOMYG00000001764
Gene Symbol: INSRA
1 Cross references
204 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSOMYG00000028616
Gene Symbol: IGF1RA
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).